Frauenfeld, 11 May 2023
Press release
New stock exchange ticker symbol for DocMorris: DOCM (formerly ROSE)
As of today, the ticker symbol for the shares of DocMorris AG – formerly Zur Rose Group AG – traded on the SIX Swiss Exchange is now "DOCM". ISIN and Valor remain unchanged.
The Annual General Meeting approved the change of name from Zur Rose Group AG to DocMorris AG on 4 May 2023.
Investors and analyst contact
Dr. Daniel Grigat, Group Head of Investor Relations Sustainability
Email: [email protected], phone: +41 58 810 11 49
Media contact
Lisa Lüthi, Group Director Communications
Email: [email protected], phone: +41 52 724 08 14
Agenda
| 17 August 2023 |
2023 Half-Year Results (11 a.m. CEST: Conference Call/Webcast) |
| 19 October 2023 |
Q3/2023 Trading Update |
DocMorris
The Swiss-based DocMorris AG is a leading company in the fields of online pharmacy, marketplace and professional healthcare with strong brands in Germany and other European countries. As Germany's largest online pharmacy, it operates DocMorris, the best-known health platform. Deliveries are mainly from the highly automated logistics centre in Heerlen, the Netherlands, with a capacity of over 27 million parcels per year. In Spain and France, the company operates the leading marketplace for health and personal care products in Southern Europe. With its business model, DocMorris offers its patients, customers and partners a broad range of products and services. In doing so, DocMorris is pursuing its vision of creating a digital health ecosystem for everyone to manage their health in one click. The company was renamed from Zur Rose Group AG to DocMorris AG in May 2023 after the Swiss business was sold to Migros/Medbase. Excluding the Swiss business, about 2,200 employees in Germany, the Netherlands, Spain, France and Switzerland generated an external revenue of CHF 1,159 million serving around 10 million active customers in 2022. The shares of DocMorris AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker DOCM). For further information, please visit corporate.docmorris.com.
